How to Achieve Medical Weight Loss in 2012

Similar documents
Causes, Temple University. School of Medicine

Which Weigh to Go? Behavior and Dietary Strategies for Weight Management March 7, 2013

New Strategies in Weight Loss

Learning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD

TO PHARMACIST: PLEASE PROVIDE THIS INFORMATION TO THE PATIENT. Important Patient Information. Patient Information about XENICAL (orlistat) Capsules

The prevalence of obesity in adults has doubled over the past 30 years

When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity

Disclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014

Clinical Update: Popular diets

WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association

Orlistat. How Alli really affects you during weight loss. JD Welch

Obesity Management in Type 2 Diabetes

MEDICAL MANAGEMENT 101

Current Management of Obesity

WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?

Overview of Management of Obesity

International Journal of Pharma and Bio Sciences COMPARISON OF EFFICACY AND SAFETY OF RIMONABANT WITH ORLISTAT IN OBESE AND OVERWEIGHT PATIENTS

What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?

OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY

Anti-Obesity Agents Drug Class Prior Authorization Protocol

Management of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.

Finding what works for weight in the workplace

When Lifestyle Modification Therapy is Not Enough: Pharmacotherapy for Severe/Complicated Pediatric Obesity

Nutritional Aspects of Obesity Management. Christy Olson MS, RD, LD, CDE

Faculty/Presenter Disclosure

How do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian

Past, Present and Future of Pharmacotherapy for Obesity

Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.

An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD

The New Trend of Anti-Obesity Drug

Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine

NEW DEVELOPMENTS IN ASSESSMENT AND TREATMENT OF OBESITY

Prevalence of Obesity (Adults) Prevalence of Obesity (Children) CURRENT STRATEGIES IN. Obesity: 33.8% Men: 32.2% Women: 35.5%

Obesity is Not about Carbohydrates:

CURRENT STRATEGIES IN OBESITY

Running head: CAN MEDICATION CURE OBESITY IN CHILDREN? 1

The ABCDs of Obesity

OBESITY IN TYPE 2 DIABETES

Lorcaserin (Belviq ) Rimonabant 2008 Sibutramine (Reductil, ) (World Health organization, WHO) 1996 WHO Orlistat (Xenical, )

Obesity D R. A I S H A H A L I E K H Z A I M Y

Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.

Disclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None

Understanding Obesity: The Causes, Effects, and Treatment Options

Lecture 18: Weight Management. Celebrity Role Models? Celebrity Role Models? Nutrition 150 Shallin Busch, Ph.D.

You should try to lose some weight : an evidence- based approach to diet and weight loss Ridge Meadows Hospital Grand Rounds 14 September 2015

Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home

8/27/2012. Mississippi s Big Problem. An Epidemic Now Reaching Our Children. What Can We Do?

Where are we heading?

Obesity the global epidemic

Patient Group Direction for the Supply of Orlistat (Xenical) from Designated Community Pharmacies

Overweight and Obesity on the Menu. Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University

Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes. Stephen D. Sisson MD

Update on the Recent Advances in Obesity Management. Benjamin O Donnell, MD Oct 5 th, 2018

Part 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.

Realistic Expectations: Drugs in the Treatment of Obesity. Lora Cotton, D.O. January 20, 2013

Obesity Management in Women

NUTRITION INTERVENTIONS FOR WEIGHT LOSS. Paul Blakeslee RD, LD, CNSC September 17 th 2017

Treatment Options for Obesity: Lifestyle and Pharmacotherapy

Obesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10%

Macronutrients and Dietary Patterns for Glucose Control

For Personal Use Only. Any commercial use is strictly prohibited. Role of glucagon-like peptide 1 receptor agonists in management of obesity

The US FDA, EMA and our TGA use these cutpoints in assessing drug efficacy. Disclosures: Professor John B Dixon

OBESITY- A GLOBAL PANDEMIC CHALLENGES IN HEALTH INITIATIVES AND IMPLICATION NOR SHAFFINAZ YUSOFF AZMI JABATAN PERUBATAN HOPSITAL SULTANAH BAHIYAH

Behavioral and Psychosocial Influences on Weight Control: Application to Pregnancy

Role of Partial Meal Replacement in Obesity Management

Which Comes First: Overeating or Obesity? Reinterpreting the 1 st Law of Thermodynamics

Obesity Treatment Update

,. (body mass index, BMI) 30 BMI 27. , (afferent signal), (efferent signal) T able 1.

Update in Obesity: the 10 Most Interesting Studies in DGIM Grand Rounds January 26, 2010

THE PERENNIAL STRUGGLE TO LOSE WEIGHT AND MAINTAIN: WHY IS IT SO DIFFICULT?

Dietetic Interventions in Complex Obesity. Therese Coleman Dietitian Medfit Proactive Healthcare & National Rehabilitation Hospital

The Current and Emerging Knowledge and Research on Non-Nutritive Sweeteners. November 16, 2018 (1-2 PM EST)

A SYSTEMATIC APPROACH TO

Healthy weight 18.5 to <25. Diabetes Dispatch. Overweight 25 to <30. Obese class I 30 to <35. Obese class II 35 to <40

BASELINE TRAITS AS PREDICTORS OF SUCCESS IN MEDICAL WEIGHT MANAGEMENT

New Drug Targets for the Treatment of Obesity

Copyright 2017 by Sea Courses Inc.

Treatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY

Faculty Disclosures. Vera Tarman, MD, Author:

Can 100 Calories/Day Make a Meaningful Difference for Weight Control

Losing weight (and keeping it off) calls for changes to how you live your life, as well as to your connection to food and exercise.

ACTIVO-I Study Report A Retrospective Prescription Event Monitoring for Safety and Efficacy of Bioactives in the Management of Overweight and Obesity

The Latest Skinny FAT

Weight management. Summary. Ian D. Caterson, Human Nutrition Unit, The University of Sydney, Sydney. Adipose tissue. Prevalence of obesity

UPDATE ON PHARMACOTHERAPY FOR WEIGHT CONTROL AND

L III: DIETARY APPROACH

OBESITY. Caroline Steinman DO

Obesity isn t Simple: Identifying Complex, Evidence-based Strategies to Treat Obesity Seriously

YOUR PERSONALIZED WEIGHT LOSS ANALYSIS

NUTRITION IN CHILDHOOD

APA Research Paper (Mirano)

Eat Well & Keep Moving Principles of Healthy Living

Lecture 3: Digestion and Dieting Physiology

1 Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Endocr Pract. 2012;18: Depression. Cancer. Gallbladder Disease

EATING AND EXERCISE. goals, whether they are physical fitness, weight loss, or hormonal/fertility improvement.

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

OBESITY: The Growing Epidemic and its Medical Impact

Popular Diets: A Scientific Review

Limiting choice as an approach for obesity management. Jenna Crown PDt Nova Scotia Health Authority

Transcription:

How to Achieve Medical Weight Loss in 2012 Gary D. Foster, Ph.D. Laure H. Carnell Professor of Medicine, Public Health, and Psychology Director, Center for Obesity Research and Education Temple University Overview Rationale and Barriers Behavioral Treatment Dietary Treatment Pharmacological Treatment Patient Expectations

Rationale For Treating Obesity Many OSA patients are obese Reductions in weight are associated with improvements in SDB Reductions in weight improve many comorbidty conditions that obesity and OSA share Barriers Fatigue One more thing to do Multiple behavior changes

Obesity Treatment Guidelines The Practical Guide can be found at: NHLBI web site: www.nhlbi.nih.gov The Obesity Society web site: www.obesity.org Guide for Selecting Obesity Treatment BMI Category (kg/m 2 ) Treatment 25-26.9 27-29.9 30-34.9 35-39.9 >40 Diet, Exercise, Behavior Tx Pharmacotherapy Surgery + + + + + With comorbidities + + + With comorbidities + The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. October 2000, NIH Pub. No.00-4084

Antecedent Behavior Consequence A Sample Behavior Chain Buy Cookies Leave Cookies on Counter Home on Saturday Afternoon Tired and Bored Eat While Watching TV Take Cookies to TV Room Go to Kitchen Urge to Eat Eat Rapidly Until Full Feel Guilty/ Like a Failure Restraint Weakens Further More Eating Brownell KD. The LEARN Program for Weight Control. 7th ed. American Health Publishing Co; 2003.

Self-Monitoring Food Intake Types of foods Portion sizes Calories (reduce by 500 kcal/d) Times, places, and activities Thoughts and moods Brownell: Learn Program for Weight Control, 1998

The Dieter s Dilemma Weight Loss with a Low-Carbohydrate, Mediterranean, or Low Fat Diet Sample description N=322 277 Male, 45 Female Age 52+7 BMI 30.9+3.6 Randomly assigned to 1 of 3 conditions Low-fat, restricted calorie Mediterranean, restricted calorie Low-carbohydrate, non-restricted calorie Shai et al. NEJM, 2008

Low-fat, restricted calorie (n=104) 1500 kcal/day for women; 1800 kcal/day men Diet based on American Heart Association guidelines 30% of calories from fats, 10% calories from saturated fats, 300 mg of cholesterol/day Mediterranean, restricted calorie (n=109) 1500 kcal/day for women; 1800 kcal/day men Diet rich in vegetables, low in red meat (replaced with fish or poultry) >35% of calories from fat Main source of added fats were 30 to 45 g of olive oil and a handful of nuts Low-carbohydrate, non restricted calorie (n=109) 20g of carbohydrates/day for induction phase with a gradual increase to a max of 120 g/day Diet based on the Atkins diet Diet Plans Shai et al. NEJM, 2008 Weight Changes during 2 Years According to Diet Group Shai et al. NEJM, 2008

Comparison of Low-Carbohydrate and Low-Fat Diets for Obesity: A Two-Year, Multi-Center Randomized Trial 317 Participants (208 women, 99 men) 45.5 ± 9.7 years old 36.1 ± 3.5kg/m 2 BMI 74.9% European American Participants were randomly assigned to either: Low-carbohydrate diet: Limited carbohydrate intake with unrestricted consumption of fat and protein. Low-fat diet: Limiting energy intake to 1200 to 1500 kcal/d for women and 1500 to 1800 kcal/d for men, with approximately 55 percent of calories from carbohydrate, 30 percent from fat, and 15 percent from protein. All participants received group behavior treatment for 2 years. Foster et al. Ann Intern Med, 2010 Weight Loss 0 Change in Weight (kg) -2-4 -6-8 -10-12 -14 Low-fat Low-carbohydrate 3 6 12 24 Month Foster et al. Ann Intern Med, 2010

Lipid Changes * * * * * Foster et al. Ann Intern Med, 2010 Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates Sample description (N=811) 515 female, 296 male Age 51.9 ± 9 years old BMI 33 ± 4.0kg/m 2 Weight 93 ±16 kg All participants were offered group and individual instructional sessions for 2 years. Sacks et al. NEJM, 2008

POUNDS LOST: Diets Diet Protein Fat Carbohydrate Orange 25% 40% 35% Green 15% 40% 45% Pink 25% 20% 55% Blue 15% 20% 65% Sacks et al. NEJM, 2008 POUNDS LOST: Body weight Over 2 Yrs, ITT 0-1 -2-3 -4-5 Diet Composition Carbohydrate/Protein/Fa t (% energy) 65/15/20 55/25/20 45/15/40 35/25/40-6 -7 0 6 12 18 24 Months Sacks et al. NEJM, 2008

Portion-Controlled Meals Provide fixed-portion and calorie amounts Reduce choices and contact with problem foods Are convenient to use Satisfy appetite (monotony and sensory specific satiety) Facilitate dietary adherence Meal Replacements Enhance Initial and Long-term Weight Loss Percentage Weight Loss 0 5 10 15 Phase 1* CF MR-2 Phase 2 MR-1 0 2 4 6 8 10 12 18 24 30 36 45 51 *1200 1500 kcal/d diet prescription. Time (mo) CF=conventional foods. MR-2=replacements for 2 meals, 2 snacks daily. MR-1=replacements for 1 meal, 1 snack daily. Ditschuneit et al.,am J Clin Nutr, 1999 Fletcher-Mors et al., Obes Res, 2000

Meta-Analysis of Partial Meal Replacements (PMR) vs. Reduced Calorie Diets (RCD) Mean Weight Losses for Completers Weight Loss (in kg) 4 2 0-2 -4-6 -8-10 *p<.001 *p<.001-4 -4.4-6.5-7 3 months 12 months RCD PMR Heymsfeld et al. IJO, 2003

Antiobesity Agents: How They Work Agents Releasing Agent Reuptake Inhibitor Selective Lipase Inhibitor 5-HT NE DA 5-HT NE DA Dexamphetamine +++ +++ Phentermine Sibutramine +++ +++ +++ +++ + Orlistat +++ 5-HT = serotonin; NE = noradrenaline; DA = dopamine 1 Bray, Ann Intern Med., 1993., 2 Beales, Kopelman PharmacoEconomics. 1994., 3 Buckett et al. Prog Neuropsychopharmacol Biol Psychiatry. 1988., 4 Drent et al. In J Obes Relat Metab Disord., 1995., 5 Heal et al. Psychopharmacology (Berl), 1992. Drugs Approved by FDA for Treating Obesity Status Generic Name Trade Name Rx Orlistat Xenical OTC (Approved 2/07) Orlistat60mg alli Rx (Withdrawn) Sibutramine Meridia Not approved in U.S. (Withdrawn in Europe) Rimonabant Acomplia/Zimulti

Orlistat: Weight Loss and Maintenance Over 2 Years Change in Body Weight (%) 0 1 2 3 4 5 6 7 8 9 10 11 12 Placebo Orlistat P<0.001 vs placebo at 1 and 2 years 10 0 10 20 30 40 50 60 70 80 90 100 110 Week SB DB DB SB = single blind; DB = double blind Slightly hypocaloric diet Weight maintenance (eucaloric) diet Adapted with permission from Sjöström L et al. Lancet, 1998

Orlistat: Safety Adverse Events (AEs) at 1 Year 40 30 31% Placebo, n=340 Orlistat, n=343 % 20 20% 18% 10 0 5% Fatty/Oily Stool 7% Increased Defecation 1% Oily Spotting There is concern about fat-soluble vitamin absorption 3% 10% Fecal Urgency 0% 7% Fecal Incontinence Sjöström L et al. Lancet, 1998 Treatment Guidelines Orlistat Prescribe 120 mg tid, with meals containing fat Patients should be on a nutritionally balanced, reduced-calorie diet Diet should contain approximately 30% of calories from fat Distribute fat among three meals a day Use a multivitamin daily Encourage patients to enroll in XeniCare, the orlistat patient support group

alli vs. Xenical alli Xenical Use OTC Rx Dosage 60 mg 120 mg Target Pop Overweight BMI > 27kg/m 2 or > 30 kg/m 2 (w/co-morbidities) or (without) Indication Weight loss Weight loss & Maintenance Age Range 18+ 12+ GI AEs (withdrawal rates) Behavioral Support Program 3.2 5.4 Myalliplan.com Xenicare Drug development timelines 1997 sibutramine 1999 orlistat OTC Orlistat Lorcaserin Phen/ Topiramate Bupropion + Naltrexone Bupropion + Zonisamide GLP-1 analogs Leptin + Pramlintide Rimonabant Taranabant Obipinabant

Defined Weights Dream Weight A weight you would choose if you could weigh whatever you wanted. Happy Weight This weight is not as ideal as the first one. It is a weight, however, that you would be happy to achieve. Acceptable Weight A weight that you would not be particularly happy with, but one that you could accept, since it is less than your current weight. Disappointed Weight A weight that is less than your current weight, but one that you could not view as successful in any way. You would be disappointed if this were your final weight after the program. Foster et al, J Consult Clin Psychol, 1997 Defined Weights % Reduction 1 % Reduction 2 Dream 38% 38.4% Happy 31% 30.9% Acceptable 25% 24.9% Disappointed 17% 15.7% 1 Foster et al. JCCP 65(1) 79-85 1997 2 Foster et al Arch Int Med. 161 2133-2139 2001

% Achieving Defined Weights at Week 48 (N=45, Weight loss: 16.3 + 7.2 kg) Acceptable 24% 9% Happy Dream = 0% 20% Disappointed 47% Did not reach Disappointed Weight Foster et al, J Consult Clin Psychol, 1997

Helping Patients Accept More Modest Weight Losses Be clear about what treatment can do and what it cannot do Discuss biological limits Focus on nonweight outcomes Be empathic about dissatisfaction with weight/shape